| content | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
Tazobactam
|
|
| Systematic (IUPAC) name | |
| (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-
(triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0] heptane-2-carboxylic acid |
|
| Identifiers | |
| CAS number | |
| ATC code | J01 |
| PubChem | ? |
| DrugBank | |
| Chemical data | |
| Formula | C10H12N4O5S |
| Mol. mass | 300.289 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Tazobactam is a compound which inhibits the action of bacterial beta-lactamases. It is added to the extended spectrum beta-lactam antibiotic piperacillin to produce Tazocin or Zosyn. It broadens the spectrum of piperacillin by making it effective against organisms that express beta-lactamase and would normally degrade piperacillin.
Tazobactam sodium is a derivative of the penicillin nucleus and is a penicillanic acid sulfone.
External links
|
||||||||||||||||||||||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
